|
|
Prof. George Whitesides, co-Founder Currently the Woodford L. and Ann A Flowers University Professor at Harvard University, Prof. George Whitesides joined Harvard’s Department of Chemistry in 1982 and served as Department Chairman from 1986 to 1989. Prior to joining Harvard, he was a member of the faculty of the Massachusetts Institute of Technology from 1963 to 1982. His present research interests include materials science, biophysics, surface science, polyvalency, microfluidics, optics, self-assembly, microfabrication, nanotechnology, and cell surface biochemistry. Dr. Whitesides has held advisory positions on the National Research Council, National Science Foundation, and the Department of Defense’s Defense Advanced Research Projects Agency (DARPA), and is a member of the American Academy of Arts and Sciences, National Academy of Sciences, National Academy of Engineering, and the American Philosophical Society, among other organizations. He has received dozens of honors, including the American Chemical Society (ACS) Award in Pure Chemistry (1975), the Arthur C. Cope Award (1995), the DARPA Award for Significant Technical Achievement (1996), the National Medal of Science (1998), the Von Hippel Award (2000), the Dan David Award (2005), the Welch Award (2005), and the Priestley Award (2007). Dr. Whitesides is a co-founder of companies with a combined market capitalization of over $20 billion. Dr. Whitesides he received an A.B. from Harvard University in 1960 and a Ph.D. from the California Institute of Technology in 1964.
|
|
|
Dr. Marvin Slepian, co-Founder Dr. Slepian is Professor of Medicine (Cardiology), Director of Interventional Cardiology, and Director of the Tissue Engineering Lab at the University of Arizona. Dr. Slepian completed his Internal Medicine training at NYU-Bellevue in New York where he was a Resident and Chief Resident in Medicine. He completed his Cardiology training at Johns Hopkins where he was a Clinical and Research Fellow. He completed a second fellowship in Interventional Cardiology at the Cleveland Clinic. Dr. Slepian has conducted extensive research, development and pre-clinical investigation of novel cardiovascular therapeutic methods and devices, and is the holder of more than 25 issued and 41 filed patents. He is an expert in polymeric biomaterials and local drug delivery.Dr. Slepian has founded numerous medical device companies, including Syncardia Systems, Focal (NASDAQ-traded, acquired by Genzyme), Endotex, Angiotrax, and Hansen Medical (NASDAQ-HNSN), and has served as acting CEO and Board Member of several medical device startups. He earned his AB in Biochemical Sciences and Science in Human Affairs from Princeton University, and his M.D. from the University of Cincinnati, College of Medicine, and has received additional post-doctoral training at MIT and Washington University.
|
